SILO
Silo Pharma, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Silo Pharma, Inc.
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
—
−85.19%
shares held · 6 largest managers
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| AdvisorShares | $469,364 | 52.88% | −88.62% |
| FNY Investment | $233,000 | 26.25% | new |
| Citadel | $104,328 | 11.75% | −21.67% |
| Vanguardindex-like | $74,247 | 8.37% | +6.55% |
| Vanguard Fiduciary Trustindex-like | $5,428 | 0.61% | −93.33% |
| Manager | Value | % base | |
|---|---|---|---|
| AdvisorShares | $469,364 | 52.88% | −88.62% |
| FNY Investment | $233,000 | 26.25% | new |
| Citadel | $104,328 | 11.75% | −21.67% |
| Vanguardindex-like | $74,247 | 8.37% | +6.55% |
| Vanguard Fiduciary Trustindex-like | $5,428 | 0.61% | −93.33% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Silo Pharma, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Silo Pharma, Inc..
Annual filing, covered
10-K parsed · Mar 27 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 27 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research for patients with depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland, The Regents of the University of California, and Columbia University. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research for patients with depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland, The Regents of the University of California, and Columbia University. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Silo Pharma, Inc.
1.23
+0.02 · +1.65%
post 1.27 +3.25%
Largest filed tie
—
—
—
Expected move
No implied move.